Research

In a global pandemic characterized by extreme uncertainty, governments, employers and citizens have been flung into situations they weren’t fully prepared for.

Real-world evidence is derived from curating, standardizing, and analyzing real-world data to obtain high-quality and reliable information from diverse and complex sources.

This report provides an overview of approaches to manage the pricing of preventive therapies such as novel vaccines in times of public health emergencies.

During the pandemic, businesses are asking about their potential price gouging liability in states that they do not sell into directly but where their products might end up.

The use of data from the real world to address clinical and policy-relevant questions that cannot be answered using data from clinical trials is garnering increased interest.

ICER releases update to results of its initial analyses on the pricing for remdesivir (Gilead Sciences).

Aligning the incentives of pharma companies with the needs of the public and the government is complicated. And finding a sweet spot for pricing a vaccine is vital.

Enforcement strategies for fentanyl and other synthetic opioids.

Combating sickle cell disease in India.

When a medication’s price surpasses the threshold of its cost-effectiveness.

How measurement of wellbeing might be used to set public sector priorities.

Less than a movie ticket or impossible to overpay?

The Orphan Drug Act extends exclusivity of branded drugs by 7 years for each rare disease approval.

Covid-19 has upended U.S. health care.

The vast majority of Medicare spending for prescription drugs occurs under the Medicare Part D program, which covers retail prescription drugs filled at a pharmacy, typically in pill form but sometimes injected by patients themselves.